> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # The Compounded Weight Loss Drug Business Was Built on a Shortage. The Shortage Ended, and Most Customers Never Heard - URL: https://compounded.ghost.io/the-compounded-weight-loss-drug-business-was-built-on-a-shortage-the-shortage-ended-and-most-customers-never-heard/ - Published: 2026-09-20T11:40:24.000Z - Updated: 2026-09-20T11:40:23.000Z - Author: Connor Hayes The FDA has confirmed that the national supply of semaglutide and tirzepatide has stabilized, and that neither drug appears on the agency's shortage list. That sounds like routine supply chain news. It is actually the legal foundation of an entire industry being removed, because the compounded versions of these drugs sold by telehealth companies and compounding pharmacies existed almost entirely because of the shortage designation. A great many people are still buying compounded GLP-1 medications, often without a clear sense of what has changed underneath the transaction. The rules are not complicated, and they are worth understanding before renewing a subscription. ### From the Lab to the Ledger Compounding is a long-established and legitimate part of pharmacy. A pharmacist prepares a medication for a specific patient who cannot use the commercial version, because of an allergy to a dye, a need for a liquid rather than a tablet, or a dose the manufacturer does not make. Federal law explicitly allows this without FDA approval of the preparation. What federal law does not allow is compounding something that is essentially a copy of an approved commercial product, on a regular basis or in large quantities. The FDA treats a compounded drug as a copy when it has the same active ingredient at an equivalent strength and the same delivery route as a drug you can buy, unless the prescriber documents a clinically significant difference for that individual patient. Regularly is not a vague term in practice: a state-licensed pharmacy or physician filling more than about four such prescriptions a month is outside the informal threshold the agency has used. The shortage designation suspended all of that. When a drug is in shortage, compounders may produce copies, and between 2023 and 2025 that is what happened at scale. The exemptions closed in sequence during 2025 as each shortage resolved, tirzepatide first in February and March, semaglutide in April and May, and neither drug now sits on the shortage list or the list of bulk substances that outsourcing facilities may use. The workaround the market moved to is the clinically significant difference clause. This is why so many current offerings advertise a personalized dose, an unusual strength, or an added ingredient such as a vitamin. Some of those combinations have a legitimate clinical rationale for an individual patient. Many are a formulation adjustment designed to avoid being a copy, and the FDA has said directly that it does not consider small deviations made for that purpose to be sufficient. There is a separate safety layer that predates the legal question. Compounded semaglutide is typically supplied in a vial with a syringe rather than a prefilled pen, and the agency has documented dosing errors from that arrangement, including patients drawing up five or ten times the intended amount because a dose written in milligrams was measured in units. Compounded products are also not tested or approved by the FDA for potency, purity or sterility before sale. ### Bio-Pipeline Ledger FDA-approved semaglutide and tirzepatide products: available, in stable supply, tested for potency and sterility, and supported by the clinical trials the entire category is built on. Compounded copies of those drugs made under the shortage exemption: no longer permitted. The exemptions ended in 2025 and the shortages are resolved. Patient-specific compounding for a documented clinical need: legal and unchanged, and genuinely useful for a narrow group of patients. It is not a general-purpose route to a cheaper version. Compounded products marketed as personalized doses or with added ingredients: legally contested. Some have a real rationale, and the FDA has said that formulation changes made to avoid copy status do not qualify. Research-grade or research-only peptides sold online: not medicines, not made under pharmaceutical quality standards, and not intended for human use regardless of how they are marketed. Oral and generic alternatives arriving as patents expire in various markets: a real future source of lower prices, on a timeline set by patent law rather than by the current gray market. ### The Clinical Reality Check What is established is the regulatory position, and it is unambiguous. The shortages are resolved, the exemptions that permitted mass compounding have closed, and copies of these drugs can no longer be produced at scale lawfully. Anyone still buying one is buying from a business operating in a narrowing space, whatever the website says about compliance. What is overstated in both directions is the safety conversation. Compounded medication is not inherently dangerous, and compounding pharmacies serve a real purpose. What is missing is independent verification of what is in the vial, plus a delivery format that has produced documented dosing errors. The practical step for anyone currently taking a compounded GLP-1 is a conversation with the prescribing clinician about what the plan is when the supply stops, because supply that depends on an expired exemption is not a plan. Coverage, approved products at negotiated prices, and non-drug approaches are all on the table in that conversation, and it is a better one to have on your own schedule than after a pharmacy closes. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/09/compounded-glp1-legal-status-after-shortage-1-photorealistic.jpg) ###